Kristian M. Bowles

Norwich Research Park
Norwich, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.

Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.

Journal: British journal of haematology

Published: February 28, 2026

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Journal: The Lancet. Oncology

Published: December 03, 2025

Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper.

Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper.

Journal: British journal of haematology

Published: April 09, 2024

BCL-2 inhibition in haematological malignancies: Clinical application and complications.

BCL-2 inhibition in haematological malignancies: Clinical application and complications.

Journal: Blood reviews

Published: January 10, 2024

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 14, 2023

Plasma cell-derived mtDAMPs activate the macrophage STING pathway, promoting myeloma progression.

Plasma cell-derived mtDAMPs activate the macrophage STING pathway, promoting myeloma progression.

Journal: Blood

Published: October 12, 2022

HSC-derived fatty acid oxidation in steady-state and stressed hematopoiesis.

HSC-derived fatty acid oxidation in steady-state and stressed hematopoiesis.

Journal: Experimental hematology

Published: May 04, 2022

Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche.

Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche.

Journal: Frontiers in oncology

Published: April 20, 2022

p16INK4A-dependent senescence in the bone marrow niche drives age-related metabolic changes of hematopoietic progenitors.

p16INK4A-dependent senescence in the bone marrow niche drives age-related metabolic changes of hematopoietic progenitors.

Journal: Blood advances

Published: January 11, 2022

Panhematopoietic RNA barcoding enables kinetic measurements of nucleate and anucleate lineages and the activation of myeloid clones following acute platelet depletion.

Panhematopoietic RNA barcoding enables kinetic measurements of nucleate and anucleate lineages and the activation of myeloid clones following acute platelet depletion.

Journal: Genome biology

Published: November 10, 2021

PGC-1α induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma.

PGC-1α induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma.

Journal: British journal of cancer

Published: August 09, 2021

Siglec-7 Mediates Immunomodulation by Colorectal Cancer-Associated Fusobacterium nucleatum ssp. animalis.

Siglec-7 Mediates Immunomodulation by Colorectal Cancer-Associated Fusobacterium nucleatum ssp. animalis.

Journal: Frontiers in immunology

Published: July 19, 2021

Showing 1-12 of 77

Last Updated: 09/26/2026